The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High dose alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Results from the randomized phase 3 OLIGO study.
 
Annemiek Van Ommen-Nijhof
No Relationships to Disclose
 
Tessa Gerjanne Steenbruggen
No Relationships to Disclose
 
Terry G. Wiersma
No Relationships to Disclose
 
Sara Balduzzi
No Relationships to Disclose
 
Antonios Daletzakis
No Relationships to Disclose
 
Marjo Holtkamp
No Relationships to Disclose
 
Marjolein Delfos
No Relationships to Disclose
 
Karin Beelen
No Relationships to Disclose
 
Ester Siemerink
No Relationships to Disclose
 
Joan B. Heijns
No Relationships to Disclose
 
Ingrid A. Mandjes
No Relationships to Disclose
 
Jelle Wesseling
No Relationships to Disclose
 
Efraim H. Rosenberg
No Relationships to Disclose
 
Marie-Jeanne T.F.D Vrancken Peeters
No Relationships to Disclose
 
Sabine C. Linn
No Relationships to Disclose
 
Gabe S. Sonke
Consulting or Advisory Role - Biovica (Inst); Novartis (Inst); Seagen (Inst)
Research Funding - Agendia (Inst); AstraZeneca/Merck (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)